A new study published in the journal of Clinical Gastroenterology and Hepatology showed that calcium-channel blockers (CCB) ...

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in ...

The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

ACEI and ARB use in CKD has been available for over three decades, but it is still underutilized. Now, a new clinical decision support tool may change that.

The seventh scheduled review by the Independent Data Monitoring Committee (IDMC) has been successfully completed for ...

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

Drs Kathy Miller and Bonnie Ky discuss cardiovascular concerns with HER2-targeted therapies and how to work with cardiology ...

Hypertension harms brain cells and vessels before pressure rises, triggering early molecular changes linked to dementia risk.

Bristol Myers Squibb (BMS) and Johnson & Johnson have decided to terminate a Phase III trial of their jointly developed ...

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

Papillary muscle scarring (papSCAR) as detected by dark blood delayed-enhancement cardiovascular magnetic resonance (CMR) was ...